Evidence map›Paper›PMID 40971029›Full record

ArticleMedical microbiology and immunology2025

A new bactericidal chlorinated derivative containing 2-aminooxazole potentiates antibacterial action of colistin against multidrug-resistant acinetobacter baumannii.

Adéla Diepoltová, Daria Elzbieta Nawrot, Ondřej Janďourek, Martin Juhás, Pavel Bárta, Pavlína Vávrová, Vinod Sukanth Kumar Pallabothula, Paulína Dudášová-Hatoková, Marcela Vejsová, Barbora Voxová and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical microbiology and immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Adéla DiepoltováFaculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 03, Hradec Králové, Czech Republic.
Daria Elzbieta NawrotFaculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 03, Hradec Králové, Czech Republic.
Ondřej JanďourekFaculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 03, Hradec Králové, Czech Republic.
Martin JuhásFaculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 03, Hradec Králové, Czech Republic.
Pavel BártaFaculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 03, Hradec Králové, Czech Republic.
Pavlína VávrováFaculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 03, Hradec Králové, Czech Republic.
Vinod Sukanth Kumar PallabothulaFaculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 03, Hradec Králové, Czech Republic.
Paulína Dudášová-HatokováFaculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 03, Hradec Králové, Czech Republic.
Marcela VejsováFaculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 03, Hradec Králové, Czech Republic.
Barbora VoxováFaculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 03, Hradec Králové, Czech Republic.
Jan ÖsterreicherFaculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 03, Hradec Králové, Czech Republic.
Petra Štěrbová-KovaříkováFaculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 03, Hradec Králové, Czech Republic.
Petr NachtigalFaculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 03, Hradec Králové, Czech Republic.
Jan ZitkoFaculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 03, Hradec Králové, Czech Republic.
Klára KonečnáFaculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 03, Hradec Králové, Czech Republic. konecna@faf.cuni.cz.ORCID http://orcid.org/0000-0001-5670-7767

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This comprehensive study provides insight into the antibacterial action of a recently published 2-chloro-N-(oxazol-2-yl)isonicotinamide (AB15), intending to assess its potential as a candidate adjuvant molecule to support existing antibacterial drugs. Within the determination of the antibacterial effect, a promising activity against a member of the ESKAPE group with reduced treatment options, biofilm producer, Acinetobacter baumannii, was recognized (MIC of AB15 ranged from 15.63 to 62.5 µM). In addition, AB15 exhibited bactericidal activity and non/low-toxicity in vitro (IC

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsColistinDrug Resistance, Multiple, BacterialOxazolesAcinetobacter InfectionsAnimalsBiofilmsCell LineDrug SynergismHumansLarvaMicrobial Sensitivity TestsMothsAnti-Bacterial AgentsColistinOxazoles2-aminooxazoleAcinetobacter baumanniiAnti-biofilm activityAntimicrobial resistanceCheckerboard synergy study

Identifiers

PMID40971029
PMCPMC12449380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.